Autopsy report · NCT05403541
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Cause of deathFunding or business
“Sponsor Decision”
Life of this trial
- Registered 1 month before it started.
- Ran for about 4 years 1 month before it stopped.
- 233 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Immunovant Sciences GmbH
- Sponsor type
- Industry
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Batoclimab 680 mg SC weekly; Batoclimab 340 mg SC weekly; Matching Placebo SC; Batoclimab 340 mg SC bi-weekly
- Participants
- 233
- Sites
- 93
- Countries
- Argentina, Brazil, Canada, Georgia, Germany, Hungary, Italy, Japan, Mexico, Poland, Romania, Serbia and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.